Navigation Links
Neogen Acquires VeroMara from GlycoMar Ltd.
Date:6/20/2011

LANSING, Mich., June 20, 2011 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today that it has acquired the assets of the VeroMara seafood testing laboratory from its parent company, GlycoMar Ltd.

Based in Oban, Scotland, VeroMara offers testing services to the shellfish and salmon aquaculture industries. VeroMara's services include testing for shellfish toxins, general foodborne pathogens, including E. coli, noroviruses, and salmon husbandry. VeroMara recorded revenues of approximately $800,000 (U.S.) in its most recently completed fiscal year. Terms of the acquisition were not disclosed.

"The acquisition of VeroMara deepens Neogen's advancement into the aquatic sciences," said James Herbert, Neogen's CEO and chairman. "VeroMara's services are complementary and a nice fit with our existing product lines for the seafood industry, including one of our biggest food safety diagnostic products — our histamine tests for the tuna industry. The VeroMara purchase also provides Neogen with key collaborative relationships with influential aquaculture partners, and increased access to important international markets.

"Our new operation in Oban will work in close cooperation with our Neogen Europe headquarters in Ayr, Scotland, providing expanded products and services to a larger customer base," Herbert continued. "Our sales and marketing operations in Ayr have the capability to expand VeroMara's business to several other European countries."

"The sale of our VeroMara testing service allows GlycoMar to focus on our core business — marine natural product research and development," said Dr. Charles Bavington, GlycoMar's managing director. "We are pleased to have VeroMara join Neogen, a company we respect as being one of the world leaders in food safety. This transition will guarantee uninterrupted quality service to our customers."

In addition to its comprehensive line of rapid foodborne pathogen, sanitation monitoring and histamine tests that it offers the seafood industry, Neogen recently released rapid tests to detect toxins in shellfish that cause amnesic shellfish poisoning (ASP) and diarrhetic shellfish poisoning (DSP). The detection of ASP and DSP toxins has been a key service VeroMara has offered its customers.

Neogen Corporation develops and markets products dedicated to food and animal safety. The company's Food Safety Division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. Neogen's Animal Safety Division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants, and rodenticides.

Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's most recently filed Form 10-K.


'/>"/>
SOURCE Neogen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. William T. Boehm Joins Neogens Board of Directors
2. Neogen Reports 27% Increase in Quarterly Net Income
3. Neogens Rapid Test for Salmonella enteritidis Receives FDA Approval
4. Neogen Names Quinlan as CFO
5. Neogen Reports 33% Increase in Net Income
6. Neogen Corporation Announces 2nd Quarter Results Conference Call
7. Neogens Rapid Test for Salmonella enteritidis Receives AOAC Approval
8. NeoGenomics Schedules its Q2 2010 Earnings Release for July 29, 2010
9. NeoGenomics to Present at Noble Financials 6th Annual Equity Conference on Monday, June 7th
10. Neogen Corporation Announces 3rd Quarter Results Conference Call
11. Neogen Reports 18% Increase in Net Income
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... BEACH, Fla. , Feb. 16, 2017 /PRNewswire/ ... company revolutionizing the development of liquid biopsy tests ... has entered into an exclusive license agreement with ... distribute MDNA,s proprietary liquid biopsy test for prostate ... South Korea . This is the ...
(Date:2/16/2017)... --  Biostage, Inc. (Nasdaq: BSTG ), ... organ implants to treat cancers and other life-threatening conditions ... closing on February 15, 2017 of its previously announced ... warrants to purchase 20,000,000 shares of common stock, for ... priced at $0.40 per share of common stock, with ...
(Date:2/16/2017)...  Champions Oncology, Inc. (NASDAQ: CSBR ), ... advanced technology solutions and products to personalize the development ... of new cohorts of PDX models to their existing ... Champions, product line in hepatocellular cancer, breast cancer, castrate ... non-small cell lung cancer (including EGFR mutation; ALK/ROS1 positive) ...
(Date:2/16/2017)... NEW YORK , Feb. 16, 2017 /PRNewswire/ ... their $7M Series B financing, adding an additional $3M ... led by Mesa Verde Venture Partners and other strategic ... be directed towards further accelerating commercial adoption of their ... profiling test and expanding the Paradigm cancer registry. ...
Breaking Biology Technology:
(Date:1/19/2017)... SANTA CLARA, Calif. , Jan. 19, 2017 ... Valley company enhancing user experience and security for ... provider of next-generation payment processing systems and cybersecurity ... assist more banks, enterprises and financial institutions worldwide ... As part of the end-to-end secure user authentication ...
(Date:1/18/2017)... Jan. 18, 2017 MedNet Solutions ... supports the entire spectrum of clinical research, is ... record-breaking year for the organization in terms of ... MedNet,s eClinical products and services. The company,s exceptional ... success of iMedNet ™ ...
(Date:1/12/2017)... , Jan. 12, 2017  Trovagene, Inc. (NASDAQ: ... (ctDNA) technologies, today announced that it has signed agreements ... and the Middle East ... milestone marks the first wave of international distribution agreements ... and blood samples. The initial partners will ...
Breaking Biology News(10 mins):